Denver Nephrology

1. AstraZeneca Pharmaceuticals LP $674,882 18 payments
2. Retrophin, Inc. $605,157 407 payments
3. Novartis Pharmaceuticals Corporation $344,940 1 payment
4. AbbVie, Inc. $3,268 1 payment

1. A Phase 3, Randomized, Double-blind, Placebo-controlled Study of BION-1301 in Adults With IgA Nephropathy (The BEYOND Study) $344,940 1 payment
2. 021Igan17001 $290,883 247 payments
3. TA description Cardiovascular Renal and Metabolism Indications Chronic Kidney Disease Study status Ongoing Phase descripton Phase 3 Category R&D Sponsored Delivery model Internal $240,663 3 payments
4. A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria $149,671 1 payment
5. NEUTRALIZE - Lokelma Metabolic Acidosis Study A double-blind randomized placebo-controlled parallel design multicenter phase IIIb study of Lokelmas effect on serum potassium and serum bicarbonate in patients with CKD hyperkalemia and metabolic acidosis of CKD $132,988 6 payments
6. 021Fsgs16010 $122,919 99 payments
7. A Phase 2b Multicenter Randomised Double blind Placebo controlled Study of Verinurad and Allopurinol in Patients with Chronic Kidney Disease and Hyperuricemia $88,794 6 payments
8. Duet $65,504 26 payments
9. Spartacus $62,672 6 payments
10. a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure $60,735 1 payment

1. Other $468,355 342 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.